Clinical trial
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath…
NCT00427583 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00427583 |
|---|---|
| Title | Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors |
| Official title | An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Malignant Peripheral Nerve Sheath Tumors |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 11 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2009 |
| First posted | Jan 29, 2007 |
| Last update posted | Aug 7, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: